ESMO 2024 | Managing side effects in prolonged treatment with trastuzumab deruxtecan
Hitomi Sakai
• 15 Sep 2024
Hitomi Sakai, MD, Showa University, Tokyo, Japan, gives an overview of strategies to manage side effects in patients receiving long-term treatment with trastuzumab deruxtecan. Key adverse effects such as nausea, vomiting, diarrhea, fatigue, and interstitial lung disease. With the duration of trastuzumab deruxtecan treatment extending, managing these side effects has become increasingly critical, especially in terms of persistent nausea and vomiting. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
